Official Title

Clinical Evaluation of the Efficacy of a Medical Device in Treatment of Toenail Onychomycosis
  • Phase

    N/A
  • Study Type

    Interventional
  • Status

    Completed No Results Posted
  • Study Participants

    112
This study evaluates the effect of the medical device "Excilor® Fungal Nail Infection" in the treatment of toenail onychomycosis. Half of the participants will receive the tested product and the other half will receive a comparator (Amorolfin 5%). Patients will be followed during 6 months.
Study Started
Jan 31
2015
Primary Completion
Nov 30
2015
Study Completion
Nov 30
2015
Last Update
Sep 21
2017

Device Excilor

Drug Loceryl 5%

Excilor Experimental

2 applications per day for 6 months

Loceryl 5% Active Comparator

1 application per week for 6 months

Criteria

Inclusion Criteria:

Subject having given her/his informed, written consent,
Subject cooperative and aware of the modalities of use and the necessity and duration of the controls so that perfect adhesion to the protocol can be expected.
Subject being psychologically able to understand information and to give their/his/her consent.
Age: more than 18 years.
Subject with superficial onychomycosis on at least one great toenail or light to moderate disto-lateral onychomycosis (without matrix involvement and involvement <2/3 of the tablet).
Subject with positive results of KOH staining.
Subject having stopped any systemic antifungal treatment since at least 6 months before inclusion and/or any topical antifungal treatment since at least 3 months before inclusion.
Female subjects of childbearing potential should use an accepted contraceptive regimen since at least 12 weeks before the beginning of the study, during all the study and at least 1 month after the study end.

Exclusion Criteria:

Subject considered by the Investigator likely to be non-compliant with the protocol.
Patient enrolled in another clinical trial during the test period.
Woman being pregnant, nursing or planning a pregnancy during the course of this study.
Subject having a known allergy to one of the constituents of the tested products.
Patient suffering from serious or progressive diseases (to investigator's discretion), such as diabetes, peripheral circulatory disease, HIV, psoriasis, lichen planus, immunosuppressive pathology….
Subject with cutaneous pathology on studied zone (other than onychomycosis like angioma, dermatitis…).
No Results Posted